A safety review conduced by the US Food and Drug Administration has found no evidence that bisphosphonates, a popular type of bone-building medicine for osteoporosis, causes heart problems like atrial fibrillation.
The verdict may help remove uncertainty over drugs in this class, which had combined US sales of over $4.6 billion last year, and includes: Swiss drug major Roche's Boniva (ibandronate sodium); Reclast (zoledronic acid) and Aredia (pamidronate disodium), both made by Novartis; Merck & Co's Fosamax (alendronate); Procter & Gamble's Didronel (etidronate); Sanofi-Aventis' Skelid (tiludronate); and Actonel (risedronate), which is co-marketed by P&G and the French drug major's US unit.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze